Leptospirosis vaccines: Past, present, and future

Journal of Postgraduate Medicine

Volumn 51, Issue 3, 2005, Pages 210-214

  Koizumi, N ^a   Watanabe, H ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Cellular immunity; Genome; Killed whole cell vaccine; Leptospira; Leptospirosis; LPS; Protein antigen; Serovar; Vaccine

Indexed keywords

INACTIVATED VACCINE; PROTEIN; PROTEIN LIPL32; PROTEIN LIPL41; PROTEIN OMPL1; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; CONFERENCE PAPER; HUMORAL IMMUNITY; LEPTOSPIRA; LEPTOSPIROSIS; NONHUMAN; SEROTYPE;

ANTIGENS, BACTERIAL; BACTERIAL VACCINES; HUMANS; LEPTOSPIRA; LEPTOSPIROSIS;

EID: 28944435503     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. Levett PN. Leptospirosis. Clin Microbiol Rev 2001;14:296-326.
2. Vinetz JM. Leptospirosis. Curr Opin Infect Dis 2001;14:527-38.
3. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003;3:757-71.
4. Wani H. Ueber die Prophylaxe der Spirochaetosis icterohaemorrhagica Inada (Weilschen Krankheit) durch schutzimpfung. Zeitschrift für Immunitätsforschung und Experimentelle Therapie 1933;79:1-26.
5. Babudieri B. Vaccine against leptospirosis. Fifth international meeting of biological standardization. Science Press of Israel: Jerusalam, the Weizmann; 1959. p. 313-50.
6. Chen TZ. Development and present status of leptospiral vaccine and technology of vaccine production in China. Jap J Bacteriol 1985;40:755-62.
7. Sánchez RM, Sierra AP, Suárez MB, Álvarez ÁM, Hernández JM, González MD, et al. Evaluation of the effectiveness of a new vaccine against human leptospirosis in groups at risk. Rev Panam Salud Pública 2000;8:385-92.
8. Martínez R, Pérez A, Quiñones M del C, Cruz R, Álvarez Á, Armesto M, et al. Efficacy and safety of a vaccine against human leptospirosis in Cuba. Rev Panam de Salud Pública 2004;15:249-55.
9. Kitaoka M, Inoue S. Standard procedures of Weil's disease vaccine and Weil's disease and Akiyami combined vaccine (Japanese in original). Jpn Med J 1952;1478:2845-7.
10. Nomura S, Kishie B, Yoshikawa H, Noro M, Sakurai N, Akatsuka Y, et al. Case reports on Weil's disease in Kumano district, Mie prefecture and vaccination (Japanese in original). Media-circle 1971;140:16-25.
11. Torten M, Shenberg E, Gerichter CB, Neuman P, Klingberg MA. A new leptospiral vaccine for use in man. II. Clinical and serologic evaluation of a field trial with volunteers. J Infect Dis 1973;128:647-51.
12. Martínez SR, Obregón Fuentes AM, Pérez SA, Baly GA, Díaz GM, Baró SM, et al. The reactogenecity and immunogenecity of the first Cuban vaccine against human leptospirosis. Rev Cubana Med Trop 1998;50:159-66.
13. Sánchez RM, Sierra AP, Obregón Fuentes AM, González IR, Gil AB, Suárez MB, et al. Reactogenecity and immunogenecity of Cuban trivalent inactivated vaccine against human leptospirosis in different vaccination schedules. Rev Cubana Med Trop 2002;54:37-43.
14. Fukumura K. Epidemiological studies on the leptospirosis in Okinawa Part 1. Prevalence of the leptospirosis in Izena island and the prevention by vaccination. Yamaguchi Igaku 1984;33:257-68.
15. Philip NA, Tennent RB. Leptospirosis: a report from one practice on the use of a leptospiral vaccine for a period of three years. N Z Med J 1966;65:13-9.
16. nd edn. MediSci: Melbourne; 1999.
17. Wohl, JS. Canine leptospirosis. Compedium on Continuing Education for Practicing Veterinarian 1996;18:1215-41.
18. Klaasen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Microbiol 2003;95:121-32.
19. Shenberg E. Growth of pathogenic Leptospira in chemically defined media. J Bacteriol 1967;93:1598-606.
20. Shenberg E, Torten M. A new leptospiral vaccine for use in man. I. Development of a vaccine from Leptospira grown on a chemically defined medium. J Infect Dis 1973;128:642-6.
21. Annual report of Ministry of Health. Studies on the improvement of the leptospiral vaccine (Japanese in original). 1979.
22. Rathinam SR. Ocular leptospirosis. Curr Opin Ophthalmol 2002;13:381-6.
23. Yan Y, Chen Y, Liou W, Ding J, Chen J, Zhang J, et al. An evaluation of the serological and epidemiological effects of the outer envelope vaccine to leptospira. J Chin Med Assoc 2003;66:224-30.
24. Addamiano L, Babudieri B. Water strains of Leptospira in the serodiagnosis of human and animal leptospirosis. Bull World Health Organ 1968;39:925-34.
25. Turner LH. Leptospirosis. II. Serology. Trans R Soc Trop Med Hyg 1968;62:880-99.
26. Gussenhoven GC, van der Hoorn MA, Goris MG, Terpstra WJ, Hartskeerl RA, Mol BW, et al. LEPTO dipstick, a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human sera. J Clin Microbiol 1997;35:92-7.
27. Smits HL, Ananyina YV, Chereshsky A, Dancel L, Lai-A-Fat RF, Chee HD, et al. International multicenter evaluation of the clinical utility of a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human serum specimens. J Clin Microbiol 1999;37:2904-9.
28. n units in the antigenic polysaccharides from Leptospira biflexa serovar patoc strain Patoc I. Carbohydr Res 2000;328:517-24.
29. Matsuo K, Isogai E, Araki Y. Utilization of exocellular mannan from Rhodotorula glutinis as an immunoreactive antigen in diagnosis of leptospirosis. J Clin Microbiol 2000;38:3750-4.
30. Gorin PA, Horitsu K, Spencer JF. An exocellular mannan, alternately linked 1, 3-b and 1, 4- b from Rhodotorula glutinis. Can J Chem 1965;43:950-4.
31. Matsuo K, Isogai E, Araki Y. Control of immunologically crossreactive lept ospiral infection by administration of lipopolysaccharides from a nonpathogenic strain of Leptospira biflexa. Microbiol Immunol 2000;44:887-90.
32. Haake DA, Walker EM, Blanco DR, Bolin CA, Miller MN, Lovett MA. Changes in the surface of Leptospira interrogans serovar grippotyphosa during in vitro cultivation. Infect Immun 1991;59:1131-40.
33. Haake DA, Champion CI, Martinich C, Shang ES, Blanco DR, Miller JN, et al. Molecular cloning and sequence analysis of the gene encoding OmpL1, a transmembrane outer membrane protein of pathogenic Leptospira spp. J Bacteriol 1993;175:4225-34.
34. Shang ES, Summers TA, Haake DA. Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun 1996;64:2322-30.
35. Haake DA, Martinich C, Summers TA, Shang ES, Pruetz JD, McCoy AM, et al. Characterization of leptospiral outer membrane lipoprotein LipL36: downregulation associated with late-log-phase growth and mammalian infection. Infect Immun 1998;66:1579-87.
36. Park SH, Ahn BY, Kim MJ. Expression and immunologic characterization of recombinant heat shock protein 58 of Leptospira species: a major target antigen of the humoral immune response. DNA Cell Biol 1999;18:903-10.
37. Haake DA, Mazel MK, McCoy AM, Milward F, Chao G, Matsunaga J, et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect Immun 1999;67:6572-82.
38. Haake DA, Chao G, Zuerner RL, Barnett JK, Barnett D, Mazel M, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun 2000;68:2276-85.
39. Guerreiro H, Croda J, Flannery B, Mazel M, Matsunaga J, Galvão RM, et al. Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans. Infect Immun 2001;69:4958-68.
40. Branger C, Sonrier C, Chatrenet B, Klonjkowski B, Ruvoen-Clouet N, Aubert A, et al. Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus-mediated vaccination. Infect Immun 2001;69:6831-8.
41. Nally JE, Artiushin S, Timoney JF. Molecular characterization of thermoinduced immunogenic proteins Q1p42 and Hsp15 of Leptospira interrogans. Infect Immun 2001;69:7616-24.
42. Matsunaga J, Young TA, Barnett JK, Barnett D, Bolin CA, Haake DA. Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein. Infect Immun 2002;70:323-34.
43. Cullen PA, Cordwell SJ, Bulach DM, Haake DA, Adler B. Global analysis of outer membrane proteins from Leptospira interrogans serovar Lai. Infect Immun 2002;70:2311-8.
44. Haake DA, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. Infect Immun 2002;70:4936-45.
45. Palaniappan RU, Chang YF, Jusuf SS, Artiushin S, Timoney JF, McDonough SP, et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun 2002;70:5924-30.
46. Koizumi N, Watanabe H. Identification of a novel antigen of pathogenic Leptospira spp. that reacted with the convalescent mice sera. J Med Microbiol 2003;52:585-9.
47. Koizumi N, Watanabe H. Molecular cloning and characterization of a novel leptospiral lipoprotein with OmpA domain. FEMS Microbiol Lett 2003;226:215-9.
48. Cullen PA, Haake DA, Bulach DM, Zuerner RL, Adler B. LipL21 is a novel surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun 2003;71:2414-21.
49. Matsunaga J, Barocchi MA, Croda J, Young TA, Sanchez Y, Siqueira I, et al. Pathogenic Leptospira species express surface-exposed proteins belonging to the bacterial immunoglobulin superfamily. Mol Microbiol 2003;49:929-45.
50. Artiushin S, Timoney JF, Nally J, Verma A. Host-inducible immunogenic sphingomyelinase-like protein, Lk73.5, of Leptospira interrogans. Infect Immun 2004;72:742-9.
51. Koizumi N, Watanabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 2004;22:1545-52.
52. Cullen PA, Haake DA, Adler B. Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev 2004;28:291-318.
53. Hsieh WJ, Chang YF, Chen CS, Pan MJ. Omp52 is a growth-phase-regulated outer membrane protein of Leptospira santarosai serovar Shermani. FEMS Microbiol Lett 2005;243:339-45.
54. Nally JE, Whitelegge JP, Aguilera R, Pereira MM, Blanco DR, Lovett MA. Purification and proteomic analysis of outer membrane vesicles from a clinical isolate of Leptospira interrogans serovar Copenhageni. Proteomics 2005;5:144-52.
55. Sonrier C, Branger C, Michel V, Ruvoën-Clouet N, Ganière JP, André-Fontaine G. Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine 2000;19:86-94.
56. Shang ES, Exner MM, Summers TA, Martinich C, Champion CI, Hancock RE, et al. The rare outer membrane protein, OmpL1, of pathogenic Leptospira species is a heat-modifiable porin. Infect Immun 1995;63:3174-81.
57. Erdile LF, Brandt MA, Warakomski DJ, Westrack GJ, Sadziene A, Barbour AG, et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun 1993;61:81-90.
58. Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine 1996;14:1620-6.
59. Flannery B, Costa D, Carvalho FP, Guerreiro H, Matsunaga J, Da Silva ED, et al. Evaluation of recombinant Leptospira antigen-based enzyme-linked immunosorbent assays for the serodiagnosis of leptospirosis. J Clin Microbiol 2001;39:3303-10.
60. Lee SH, Kim KA, Park YG, Seong IW, Kim MJ, Lee YJ. Identification and partial characterization of a novel hemolysin from Leptospira interrogans serovar lai. Gene 2000;254:19-28.
61. Yang CW, Wu MS, Pan MJ, Hsieh WJ, Vandewalle A, Huang CC. The Leptospira outer membrane protein LipL32 induces tubulointerstitial nephritis-mediated gene expression in mouse proximal tubule cells. J Am Soc Nephrol 2002;13:2037-45.
62. Palaniappan RU, Chang YF, Hassan F, McDonough SP, Pough M, Barr SC, et al. Expression of leptospiral immunoglobulin-like protein by Leptospira interrogans and evaluation of its diagnostic potential in a kinetic ELISA. J Med Microbiol 2004;53:975-84.
63. Kelly G, Prasannan S, Daniell S, Fleming K, Frankel G, Dougan G, et al. Structure of the cell-adhesion fragment of intimin from enteropathogenic Escherichia coli. Nat Struct Biol 1999;6:313-8.
64. Luo Y, Frey EA, Pfuetzner RA, Creagh AL, Knoechel DG, Haynes CA, et al. Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature 2000;405:1073-7.
65. Hamburger ZA, Brown MS, Isberg RR, Bjorkman PJ. Crystal structure of invasin:a bacterial integrin-binding protein. Science 1999;286:291-5.
66. Koizumi N, Watanabe H. Unpublished data.
67. Matsunaga J, Sanchez Y, Xu X, Haake DA. Osmolarity, a key environmental signal controlling expression of leptospiral proteins LigA and LigB and the extracellular release of LigA. Infect Immun 2005;73:70-8.
68. Plotkin SA. Six revolutions in vaccinology. Pediatr Infect Dis J 2005;24:1-9.
69. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-91.
70. Serruto D, Adu-Bobie J, Capecchi B, Rappuoli R, Pizza M, Masignani V. Biotechnology and vaccines:application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 2004;113:15-32.
71. Ren SX, Fu G, Jiang XG, Zeng R, Miao YG, Xu H, et al. Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature 2003;422:888-93.
72. Nascimento AL, Ko AI, Martins EA, Monteiro-Vitorello CB, Ho PL, Haake DA, et al. Comparative genomics of two Leptospira interrogans serovars reveals novel insights into physiology and pathogenesis. J Bacteriol 2004;186:2164-72.
73. Nascimento AL, Verjovski-Almeida S, Van Sluys MA, Monteiro-Vitorello CB, Camargo LE, Digiampietri LA, et al. Genome features of Leptospira interrogans serovar Copenhagen. Br J Med Biol Res 2004;37:459-77.
74. Gamberini M, Gomez RM, Atzingen MV, Martins EA, Vasconcellos SA, Romero EC, et al. Whole-genome analysis of Leptospira interrogans to identify potential vaccine candidates against leptospirosis. FEMS Microbiol Lett 2005;244:305-13.
75. Naiman BM, Alt D, Bolin CA, Zuerner R, Baldwin CL. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gd T lymphocytes. Infect Immun 2001;69:7550-8.
76. Brown RA, Blumerman S, Gay C, Bolin C, Duby R, Baldwin CL. Comparison of three different leptospiral vaccines for induction of a type 1 immune response to Leptospira borgpetersenii serovar Hardjo. Vaccine 2003;21:4448-58.
77. + gd and CD4 T cells. Infect Immun 2002;70:6147-57.
78. Diament D, Brunialti MK, Romero EC, Kallas EG, Salomao R. Peripheral blood mononuclear cell activation induced by Leptospira interrogans glycolipoprotein. Infect Immun 2002;70:1677-83.
79. de Fost M, Hartskeerl RA, Groenendijk MR, van der Poll T. Interleukin 12 in part regulates gamma interferon release in human whole blood stimulated with Leptospira interrogans. Clin Diagn Lab Immunol 2003;10:332-5.
80. + T cells. J Immunol 2003;171:1447-55.
81. Girons IS, Bourhy P, Ottone C, Picardeau M, Yelton D, Hendrix RW, et al. The LE1 bacteriophage replicates as a plasmid within Leptospira biflexa:construction of an L. biflexa-Escherichia coli shuttle vector. J Bacteriol 2000;182:5700-5.
82. Picardeau M, Brenot A, Saint GI. First evidence for gene replacement in Leptospira spp. Inactivation of L. biflexa flaB results in non-motile mutants deficient in endoflagella. Mol Microbiol 2001;40:189-99.
83. Bauby H, Saint GI, Picardeau M. Construction and complementation of the first auxotrophic mutant in the spirochaete Leptospira meyeri. Microbiology 2003;149:689-93.